Jennifer Doudna’s Scribe Therapeutics lands a $100M Series B to advance CRISPR technology
San Francisco Business Times
|
March 31, 2021
X min read
San Francisco Business Times
|
March 31, 2021
Share on Social
More like this
Media
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
July 27, 2026
Read Now
Press
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
July 27, 2026
Read Now
